Shopping Cart
Remove All
Your shopping cart is currently empty
PF-06840003 (EOS200271) is a specific and orally active IDO-1 inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $32 | In Stock | In Stock | |
| 5 mg | $50 | In Stock | In Stock | |
| 10 mg | $85 | In Stock | In Stock | |
| 25 mg | $117 | In Stock | In Stock | |
| 50 mg | $137 | In Stock | In Stock | |
| 100 mg | $216 | In Stock | In Stock | |
| 200 mg | $322 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $55 | In Stock | In Stock |
| Description | PF-06840003 (EOS200271) is a specific and orally active IDO-1 inhibitor. |
| Targets&IC50 | IDO1 (mouse):1.5 μM, dIDO1:0.59 μM, IDO1 (human):0.41 μM |
| In vitro | The s of PF-06840003 has inhibitory for hIDO-1 (IC50: 0.41 μM), mouse IDO-1 (IC50: 1.5 μM) and dog IDO-1 (IC50: 0.59 μM), respectively. It has very weak inhibitory against hTDO-2 (IC50: 140 μM). In cellular assays, PF-06840003 shows activity both in the LPS/INFγ-stimulated THP1 cells (IC50: 1.7 μM) and in the HeLa assay (IC50: 1.8 μM). PF-06840003 is a very weak inhibitory against CYPs (IC50>100 μM) except 2C19 (IC50: 78 μM). |
| In vivo | In mice, PF-06840003 reduces intratumoral kynurenine levels (>80%). In multiple preClinicalal syngeneic models in mice, It inhibits tumor growth by combinated with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours. |
| Synonyms | PF 06840003, EOS200271 |
| Molecular Weight | 232.21 |
| Formula | C12H9FN2O2 |
| Cas No. | 198474-05-4 |
| Smiles | Fc1ccc2[nH]cc(C3CC(=O)NC3=O)c2c1 |
| Relative Density. | 1.464 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (258.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.